Last €66.87 EUR
Change Today -0.71 / -1.05%
Volume 0.0
QPH On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:08 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

questcor pharmaceuticals (QPH) Snapshot

Open
€66.84
Previous Close
€67.58
Day High
€66.87
Day Low
€66.83
52 Week High
07/4/14 - €70.02
52 Week Low
07/22/13 - €34.74
Market Cap
4.1B
Average Volume 10 Days
17.1
EPS TTM
--
Shares Outstanding
61.0M
EX-Date
06/27/14
P/E TM
--
Dividend
€1.20
Dividend Yield
1.28%
Current Stock Chart for QUESTCOR PHARMACEUTICALS (QPH)

questcor pharmaceuticals (QPH) Related Businessweek News

No Related Businessweek News Found

questcor pharmaceuticals (QPH) Details

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus erythematosus and systemic dermatomyositis; and as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Its H.P. Acthar Gel is also used for the treatment of acute exacerbations of multiple sclerosis in adults; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company sells its product primarily to specialty pharmacies. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

490 Employees
Last Reported Date: 04/29/14
Founded in 1990

questcor pharmaceuticals (QPH) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $832.0K
Chief Operating Officer
Total Annual Compensation: $520.0K
Executive Vice President of Strategic Affairs...
Total Annual Compensation: $485.0K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $468.0K
Chief Scientific Officer
Total Annual Compensation: $520.0K
Compensation as of Fiscal Year 2013.

questcor pharmaceuticals (QPH) Key Developments

Questcor Pharmaceuticals, Inc.(NasdaqGS:QCOR) added to Russell 1000 Index

Questcor Pharmaceuticals, Inc. will be added to the Russell 1000 Index.

Questcor Pharmaceuticals, Inc.(NasdaqGS:QCOR) dropped from Russell 2000 Index

Questcor Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

Questcor Pharmaceuticals Enters into Collaboration Agreement for Melanocortin Therapeutics

Questcor Pharmaceuticals, Inc. has entered into a development collaboration agreement with a European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. The agreement includes a technology platform that provides Questcor with a novel library of melanocortin peptides. The company has already conducted initial preclinical evaluation on a number of peptides and from this exercise has selected lead peptides with which to move forward. Unlike Acthar and Synacthen, which are broad-acting melanocortin peptide formulations which bind to all five known melanocortin receptors, the licensed technology platform provides peptides designed to target specific melanocortin receptors that Questcor believes are particularly relevant to autoimmune and inflammatory diseases. Among other key characteristics, the peptides have been designed to minimize activation of the melanocortin 2 receptor in order to limit endogenous cortisol production and related steroid side effects. The company believes this technology platform has extensive and long term intellectual property protection. The company will initially focus on conducting formulation and manufacturing activities involving the lead peptides and performing additional preclinical research in order to match the lead peptides with lead indications for clinical development. Under the terms of the collaboration, Questcor has secured an exclusive worldwide license to the peptides and technology. Questcor will fund the development of the peptides and will have the option to acquire the technology at a later date.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QPH:GR €66.87 EUR -0.71

QPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.10 USD +0.08
CR Bard Inc $145.74 USD -0.07
Novartis AG SFr.79.65 CHF -0.35
Sanofi €75.70 EUR -0.68
View Industry Companies
 

Industry Analysis

QPH

Industry Average

Valuation QPH Industry Range
Price/Earnings 17.3x
Price/Sales 6.1x
Price/Book 11.6x
Price/Cash Flow 16.8x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUESTCOR PHARMACEUTICALS, please visit www.questcor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.